ClinicalTrials.gg
Active, not recruitingNCT04895696Updated Aug 17, 2026

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

A Phase 2 interventional study of Afimetoran and Placebo in Systemic Lupus Erythematosus, sponsored by Beeline Medicines Corporation. Active, not recruiting at 147 sites in 19 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Beeline Medicines Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
96th of 407
248 · median 70
Started
2021
with 19 others
Phase 2
120 of 477
10 open now
Primary completion
2026-06
later than 10 of 125 live
Registered
325th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 96th largest by enrollment of the 407 interventional ones that give a count, is one of 20 that started in 2021, is one of 120 in phase 2, reaches primary completion later than 10 of the 125 other live ones, and was the 325th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • BMS-986256
  • Systemic Lupus Erythematosus
  • SLE
  • Connective Tissue Diseases
  • Autoimmune Diseases
  • Immune System Diseases
  • Afimetoran
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed ≥ 12 weeks before the screening visit and qualify as having SLE according to the SLE International Collaborating Clinics (SLICC) Classification Criteria at the screening visit
  • Test positive, as determined by the central laboratory, for at least one of the following lupus related autoantibodies at the time of screening: antinuclear antibody ≥ 1:80, anti-double-stranded deoxyribonucleic acid (dsDNA) antibody, or anti-Smith antibody.
  • Have a total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score ≥ 6 points and clinical Hybrid SLEDAI score ≥ 4 points with joint involvement and/or rash

Exclusion criteria

Exclusion Criteria:

  • Active severe lupus nephritis (LN) as assessed by the investigator
  • Active or unstable neuropsychiatric lupus manifestations defined by the Hybrid SLEDAI
  • Diagnosis of Mixed Connective Tissue Disease for which the predominant diagnosis is not SLE
  • Antiphospholipid Syndrome

Other protocol-defined inclusion/exclusion criteria apply

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Afimetoran: Dose 1

    Drug: Afimetoran

  • Experimental
    Afimetoran: Dose 2

    Drug: Afimetoran

  • Experimental
    Afimetoran: Dose 3

    Drug: Afimetoran

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986256

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Proportion of participants that achieve an SLE (Systemic Lupus Erythematosus) Responder Index (4) (SRI(4)) response at Week 48

    Time frame: Up to 48 Weeks

Secondary outcomes

  1. Proportion of participants that achieve a British Isles Lupus Assessment Group (BILAG)-based Combine Lupus Assessment (BICLA) response at Week 24 and Week 48

    Time frame: Up to 48 Weeks

  2. Proportion of participants who achieve an SRI(4) response at Week 24

    Time frame: Up to 24 Weeks

  3. Proportion of participants who achieve a Lupus Low Disease Activity State (LLDAS) response at Week 24 and Week 48

    Time frame: Up to 48 Weeks

  4. Proportion of participants with a Cutaneous Lupus Erythematosus Disease Area and Severity Index; Activity (CLASI-A) score ≥ 10 at baseline who achieve a decrease of ≥ 50% from baseline CLASI-A score (CLASI-50) response at Week 24 and Week 48

    Time frame: Up to 48 Weeks

  5. Proportion of participants with 6 or more swollen joints and 6 or more tender joints at baseline who achieve a ≥ 50% reduction from baseline in both swollen and tender joints at Week 24 and Week 48

    Time frame: Up to 48 Weeks

  6. Mean change from baseline in swollen joint count using the 28-joint count at Week 24 and Week 48 in participants with ≥ 2 swollen joints at baseline

    Time frame: Up to 48 Weeks

  7. Mean change from baseline in tender joint count at Week 24 and Week 48 using the 28- joint count in participants with ≥ 2 tender joints at baseline

    Time frame: Up to 48 Weeks

  8. Change from baseline in PGA score of disease activity at Week 24 and Week 48

    PGA = Physician Global Assessment of disease activity (score of "0" indicating no disease activity and higher scores indicating higher disease activity)

    Time frame: Up to 48 Weeks

  9. Proportion of participants who achieve CS reduction or maintenance to ≤ 7.5 mg per day at Week 48

    Time frame: Up to 48 Weeks

  10. Change in participant reported disease activity from baseline to Week 24 and Week 48 according to the 36-item Short Form Health Questionnaire (SF-36)

    The SF-36 was designed as an indicator of health status in population surveys, and health policy evaluations, and for use as an outcome measure in clinical practice and research. Scores for each domain range from 0 to 100, with high scores indicating a better health status.

    Time frame: Up to 48 Weeks

  11. Number of participants with Adverse Events (AEs)

    Time frame: Up to 100 Weeks

  12. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to 100 Weeks

  13. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 100 Weeks

  14. Number of participants with physical examination abnormalities

    Time frame: Up to 100 Weeks

  15. Number of participants with vital sign abnormalities

    Time frame: Up to 100 Weeks

  16. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 52 Weeks

07

Study locations

147 sites
  • Local Institution - 0100
    Birmingham, Alabama 35205, United States
  • Local Institution - 0123
    Huntington Beach, California 92648, United States
  • Local Institution - 0170
    La Jolla, California 92037, United States
  • Local Institution - 0159
    La Palma, California 90623, United States
  • Local Institution - 0172
    San Diego, California 92128, United States
  • Local Institution - 0164
    Woodland Hills, California 91364, United States
  • Local Institution - 0121
    Clearwater, Florida 33765, United States
  • Local Institution - 0167
    Kissimmee, Florida 34741, United States
  • Local Institution - 0122
    Orlando, Florida 32808, United States
  • Local Institution - 0173
    Ormond Beach, Florida 32174, United States
  • Local Institution - 0154
    Plantation, Florida 33324, United States
  • Local Institution - 0137
    South Miami, Florida 33143, United States
  • Local Institution - 0155
    Tamarac, Florida 33321, United States
  • Local Institution - 0160
    Atlanta, Georgia 30318, United States
  • Local Institution - 0205
    Suwanee, Georgia 30024, United States
  • Local Institution - 0146
    Orland Park, Illinois 60467, United States
  • Local Institution - 0187
    Hopkinsville, Kentucky 42240, United States
  • Local Institution - 0171
    Baton Rouge, Louisiana 70836, United States
  • Local Institution - 0134
    Wheaton, Maryland 20902, United States
  • Local Institution - 0070
    Eagan, Minnesota 55121, United States
  • Local Institution - 0124
    St Louis, Missouri 63110, United States
  • Local Institution - 0165
    St Louis, Missouri 63141, United States
  • Local Institution - 0091
    Las Vegas, Nevada 89128, United States
  • Local Institution - 0219
    West Long Branch, New Jersey 07764, United States
  • Local Institution - 0140
    Manhasset, New York 11030, United States
  • Local Institution - 0132
    The Bronx, New York 10461, United States
  • Local Institution - 0203
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0103
    Charlotte, North Carolina 28211, United States
  • Local Institution - 0151
    Columbus, Ohio 43203, United States
  • Local Institution - 0042
    Middleburg Heights, Ohio 44130, United States
  • Local Institution - 0152
    Allen, Texas 75013, United States
  • Local Institution - 0197
    Allen, Texas 75013, United States
  • Local Institution - 0136
    Amarillo, Texas 79124, United States
  • Local Institution - 0029
    Mesquite, Texas 75150, United States
  • Local Institution - 0163
    San Antonio, Texas 78215, United States
  • Local Institution - 0223
    Bellevue, Washington 98004, United States
  • Local Institution - 0207
    Buenos Aires, Buenos Aires 1425, Argentina
  • Local Institution - 0128
    Buenos Aires, Buenos Aires C1426ABP, Argentina
  • Local Institution - 0130
    Quilmes, Buenos Aires 1878, Argentina
  • Local Institution - 0195
    San Fernando, Buenos Aires 1646, Argentina
  • Local Institution - 0025
    Córdoba, Córdoba Province 5004, Argentina
  • Local Institution - 0074
    Buenos Aires, Distrito Federal C1121ABE, Argentina
  • Local Institution - 0040
    CABA, Distrito Federal 1406, Argentina
  • Local Institution - 0041
    San Juan, San Juan Province 5400, Argentina
  • Local Institution - 0027
    San Miguel de Tucumán, Tucumán Province T4000, Argentina
  • Local Institution - 0063
    Botany, New South Wales 2019, Australia
  • Local Institution - 0072
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0066
    Maroochydore, Queensland 4558, Australia
  • Local Institution - 0065
    Woodville, South Australia 5011, Australia
  • Local Institution - 0062
    Camberwell, Victoria 3124, Australia
  • Local Institution - 0064
    Ivanhoe, Victoria 3079, Australia
  • Local Institution - 0006
    Salvador, Estado de Bahia 40150-150, Brazil
  • Local Institution - 0031
    Salvador, Estado de Bahia 41820-020, Brazil
  • Local Institution - 0093
    Cuiabá, Mato Grosso 78020-500, Brazil
  • Local Institution - 0008
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • Local Institution - 0010
    Curitiba, Paraná 80030110, Brazil
  • Local Institution - 0007
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • Local Institution - 0014
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • Local Institution - 0045
    São José do Rio Preto, São Paulo 15090000, Brazil
  • Local Institution - 0009
    São Paulo, São Paulo 04266-010, Brazil
  • Local Institution - 0127
    Osorno, Los Lagos Region 5290000, Chile
  • Local Institution - 0143
    Valdivia, Los Ríos Region 2279374, Chile
  • Local Institution - 0075
    Providencia, Santiago Metropolitan 7500504, Chile
  • Local Institution - 0073
    Santiago, Santiago Metropolitan 0, Chile
  • Local Institution - 0043
    Santiago, Santiago Metropolitan 7501126, Chile
  • Local Institution - 0177
    Beijing, Beijing Municipality 100029, China
  • Local Institution - 0180
    Beijing, Beijing Municipality 100144, China
  • Local Institution - 0184
    Shenzhen, Guangdong 518107, China
  • Local Institution - 0176
    Nanjing, Jiangsu 210000, China
  • Local Institution - 0188
    Nanjing, Jiangsu 210029, China
  • Local Institution - 0193
    Suzhou, Jiangsu 215006, China
  • Local Institution - 0174
    Changchun, Jilin 130000, China
  • Local Institution - 0179
    Dalian, Liaoning 116023, China
  • Local Institution - 0178
    Jinan, Shandong 250012, China
  • Local Institution - 0183
    Jining, Shandong 272011, China
  • Local Institution - 0190
    Medellín, Antioquia 050021, Colombia
  • Local Institution - 0001
    Barranquilla, 080020, Colombia
  • Local Institution - 0004
    Bogotá, 110221, Colombia
  • Local Institution - 0076
    Cali, 760042, Colombia
  • Local Institution - 0005
    Chía, 250001, Colombia
  • Local Institution - 0003
    Zipaquirá, 250252, Colombia
  • Local Institution - 0156
    Pessac, Aquitaine 33600, France
  • Local Institution - 0083
    Brest, Finistère 29609, France
  • Local Institution - 0048
    Bordeaux, 33076, France
  • Local Institution - 0144
    Caen, 14033, France
  • Local Institution - 0129
    Lille, 59037, France
  • Local Institution - 0112
    Marseille, 13003, France
  • Local Institution - 0044
    Strasbourg, 67098, France
  • Local Institution - 0087
    Cologne, North Rhine-Westphalia 50937, Germany
  • Local Institution - 0085
    Berlin, 10117, Germany
  • Local Institution - 0086
    Essen, 45122, Germany
  • Local Institution - 0084
    Freiburg im Breisgau, 79106, Germany
  • Local Institution - 0226
    Ahmedabad, Gujarat 380015, India
  • Local Institution - 0214
    Gurugram, Haryana 122001, India
  • Local Institution - 0210
    Bengaluru, Karnataka 560010, India
  • Local Institution - 0208
    New Delhi, National Capital Territory of Delhi 110029, India
  • Local Institution - 0209
    Secunderabad, Telangana 500003, India
  • Local Institution - 0106
    Dublin, Dublin D15 X40D, Ireland
  • Local Institution - 0107
    Galway, GALWAY H91 TY80, Ireland
  • Local Institution - 0119
    Manorhamilton, LEITRIM 0, Ireland

Showing the first 100 of 147 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jun 2026, 56 months.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 56 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2021
First posted
May 20, 2021
StartActual
Oct 11, 2021
Primary completionActual
Jun 12, 2026
CompletionEst.
Apr 22, 2029
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04895696
Lead sponsor
Beeline Medicines Corporation
Responsible party
Sponsor
First posted
May 20, 2021
Start date
Oct 11, 2021
Primary completion
Jun 12, 2026
Completion
Apr 22, 2029 (estimated)
Last update
Aug 17, 2026

Study contacts

Beeline Medicines Corporation
study director · Beeline Medicines Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimetoran

Start the discussion